Quibim

Quibim is a medical imaging software company that develops AI-based tools for extracting quantitative data from MRI, CT, and PET scans. The company serves both healthcare providers and life sciences organisations, with a focus on oncology, neurology, and liver disease. Its platforms and products are deployed across more than 230 sites worldwide and draw on a registry of de-identified cancer patient data and research imaging studies.

Quibim builds partnerships with biopharma companies and real-world evidence teams to support drug development programmes, including identifying candidates for clinical studies, predicting patient response to therapies, and monitoring toxicity and adverse events through AI models.

Platform: QP-Insights®

• QP-Insights® is a cloud-based, web-based platform that manages, stores, indexes, and harmonises large-scale medical imaging data and multi-omics datasets for clinical research and AI-driven radiomics studies.
• The platform standardises image quality to minimise variability in signal, contrast, and noise across different equipment manufacturers.
• QP-Insights® links imaging data with electronic health record (EHR) information and other multi-omics data sources, enabling the extraction of predictive models and new imaging biomarkers.
• The platform supports automated extraction of radiomics and deep features for clinical research and biomarker discovery.

Software as a Medical Device Products

• QP-Prostate®: An AI solution that integrates with PACS systems to support radiologists in reading prostate MRI. It provides quantitative information, automates tasks, ensures PI-RADS compliance, and aims to standardise decision-making in prostate cancer assessment.
• QP-Brain®: A brain imaging analysis tool offering volumetry and white matter hyperintensity (WMH) analysis. It provides volume and morphometry calculations to support disease classification and progression monitoring, and characterises white matter hyperintensities through advanced imaging calculations.
• QP-Liver®: A post-processing solution for liver disease management that quantifies fat and iron concentration to evaluate steatosis and iron overload. It automates segmentation of the whole abdomen and liver, reducing the time clinicians spend on manual segmentation.

Data Security and Compliance

• Quibim holds ISO 27001:2022 certification for information security management.
• Data is encrypted during storage, transfer, and at file level.
• Data processing and storage comply with both HIPAA and GDPR requirements.
• Cloud infrastructure is provided through Microsoft Azure, offering secure and scalable data storage.

Life Sciences and Research Applications

• Quibim has published case studies covering AI-based prediction of survival, neurotoxicity, and treatment response in B-cell lymphoma patients treated with CAR-T therapy.
• Additional research includes AI-driven neuroblastoma risk stratification and prognostic analysis combining genetic alterations with 18F-FDG PET/CT imaging features in diffuse large B-cell lymphoma.

Recent Developments

• Quibim has entered a partnership with Vara, a German company, to bring breast cancer screening AI to Spain.
• The company appointed Itta MacNevin as Chief Business Officer to support global growth and life sciences partnerships.
• Jeanne Bolger was appointed as an independent director and advisor to support growth in the life sciences sector.

Quibim's platform is tissue-agnostic and designed to operate at scale, drawing on one of the largest imaging data registries available for research purposes. The company positions itself at the intersection of clinical imaging, AI, and drug development support.